**From Crisis to Routine - Standardization of SARS-CoV-2 Genome Detection by Enhanced EQA Schemes in a Scientific Pandemic Network**

M Kammel et al.

**Legend to Supplementary Figure 1**

**Supplementary Figure 1: Reported Ct/Cq values for the detection of the N gene of SARS-CoV-2 in the EQA scheme June 2023**

The Ct/Cq values for sample no. 409-230613-01, EQA scheme June 2023 are presented for the detection of N gene of SARS-CoV-2.

**Box plots with black dots:** The box plots with the black dots summarize all Ct/Cq values reported by the EQA participants with their test systems used for the respective sample for the detection of the N gene. The median indicated in each of the box plots with the black dots represents the corresponding *“target gene-specific Ct/Cq median for N gene”* (generated for the specific target gene region from the reported results of all applied test systems; category 2 for Ct/Cq value consideration; see section 3.1.2).

**Box plots with blue dots:** The results are differentiated by test manufacturer and test name. Displayed are the reported Ct/Cq values of the individual test systems for N gene detection (represented by blue dots). In addition, for each manufacturer's test system, the corresponding *“assay-specific Ct/Cq median”* (generated for a defined test system from the reported results for a specific target gene region; category 3 for Ct/Cq value consideration) is given. The box for each specified test system includes its interquartile range of 50% of the data points bounded by the 75% quartile and 25% quartile. In addition, the median is plotted for all data points. The whiskers delimit 75% of the data points.

Data are shown for sample no. 409-230613-01 for which the *“target gene-specific Ct/Cq for N gene"* (according to category 2) was 29.9 (robust average calculated of all reported quantitative results for this sample – 80 360 copies/mL; see Supplementary Table 1) (Zeichhardt and Kammel, 2023a).

Abbreviations for test manufacturers:

1DR: 1Drop Diagnostics; 3DM: 3DMed Corporation; AB: Abbott; ALF: Alifax; ANA: Analtolia Geneworks; ANI: Anicon; AP: Applied Biosystems; AST: Astra Biotech; BGI: BGI Genomics; BIR: Bioron GmhH; BMX: Biomaxima; BN: Becton Dickinson; BR: BioRad; CH: Certest Biotec; CI: Cepheid; CLO: Clonit; ELI: Elisabeth Pharmacon; ER: Euro Immun; ET: ELITech; FRI: Friz Biochem; GEM: Genematrix; GEN: Genesig; GES: Genetic Signatures; GP: Geneproof; HA: Hain Lifescience; IBT: Intron Biotechnology; IDT: Integrated DNA Technologies; IG: Ingenetix; IVE: IDvet Innovative Diagnostics; LAB: Labsystems Diagnostics; LGE: Labgenomics; LIF: Liferiver; LU: Luminex; MAC: Maccura Biotechnology; MBS: Mole Bioscience; MOB: Mobidiag; NE: Neumodx; NO: Novatec; PE: Perkin Elmer; PEN: Pentabase; PIM: Priv. Inst. f. Immunol. u. Mol.genetik; PT: Pathofinder; QG: Qiagen; RO: Roche Diagnostics; SAN: Sansure Biotech; SE: Seegene; SG: Sacace Biotechnologies; SGT: Solgent; SO: Adaltis; TFS: Thermo Fisher Scientific; TM: TIB Molbiol; VIT: Vitaassay; VS: Vela Diagnostics; ZX: Laboratory developed tests/LDT; ZY: Other manufacturer; ZYB: Zybio